These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23802690)

  • 21. Phentermine/topiramate for the treatment of obesity.
    Smith SM; Meyer M; Trinkley KE
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lorcaserin: a review of its use in chronic weight management.
    Hoy SM
    Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
    Walter CP; Bleske BE; Dorsch MP
    J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.
    Halpern B; Halpern A
    Expert Opin Drug Saf; 2015 Feb; 14(2):305-15. PubMed ID: 25563411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG; Abel B; Zecca C; Saunders KH; Shukla AP
    Expert Opin Pharmacother; 2020 Jan; 21(1):21-28. PubMed ID: 31693425
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
    Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
    J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL; Crosby RD; Wang Z
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug treatment of obesity in the cardiovascular patient.
    Charakida M; Tousoulis D; Finer N
    Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
    Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
    Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB; Aronne LJ
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and safety of the new anti-obesity medications.
    Hainer V; Aldhoon-Hainerová I
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.
    Smith SR; O'Neil PM; Astrup A; Finer N; Sanchez-Kam M; Fraher K; Fain R; Shanahan WR
    Obesity (Silver Spring); 2014 Oct; 22(10):2137-46. PubMed ID: 25044799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ
    J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.